The Effects of Fisetin on Reducing Biological Aging: A Pilot Study.

Fisetin, a natural flavonoid compound, is a senolytic agent that has shown promise in extending the lifespan of aging mice. Our goal was to determine whether Fisetin can reduce human biological aging, as verified by the TruAge test. This would be the first study in healthy human adults over the age of 50 years old to determine if Fisetin can reduce their biological age. Fisetin 500 mg daily was administered for one week per month for six months. The results showed that four out of ten healthy adults experienced a reduction in biological aging, five out of ten saw an increase, and one out of ten had no change. No adverse effects were noted among the ten subjects. Telomere lengths did not statistically change with the use of Fisetin. Because five of ten had an increase in biological age, taking Fisetin as an anti- aging agent is not recommended until more extensive studies are done.

clifford B.4.1 , an allele of CG1603 , causes tissue overgrowth in the Drosophila melanogaster eye.

Mutant B.4.1 , generated via EMS mutagenesis in Drosophila melanogaster , was studied by undergraduate students participating in the Fly-CURE. After inducing genetically mosaic tissue in the adult eye, B.4.1 mutant tissue displays a robust increase in cell division and a rough appearance. Complementation mapping and sequence analysis identified a nonsense mutation in the gene CG1603 , which we named clifford ( cliff ) due to observed increases in red-pigmented mutant tissue compared to controls. cliff encodes a zinc finger-containing protein implicated in transcriptional control. RNAi knockdown of cliff similarly results in rough eyes, confirming a role for Cliff in eye development.

Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications.

Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.